Drug intelligence / Profile preview

alpha-linolenic acid-enriched triacylglycerol

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

Alpha-linolenic acid-enriched triacylglycerol (ALA-TAG) is a modified lipid in which the glycerol backbone of a triacylglycerol molecule is predominantly esterified with alpha-linolenic acid (ALA), an essential omega-3 fatty acid. This formulation increases the dietary intake of ALA beyond typical food sources. ALA-TAG is investigated for its potential to improve lipid metabolism, support cardiovascular health, and reduce risk factors associated with obesity and metabolic syndrome. Mechanistically, it serves as a source of ALA, which can be converted in the body to longer-chain omega-3 fatty acids such as EPA and DHA; these are known to exert anti-inflammatory effects and modulate lipid profiles by reducing triglycerides and possibly lowering blood pressure[1][2][4]. While standard dietary ALA has demonstrated benefits in reducing cardiovascular risk factors such as atherosclerosis and hypertension[1][8], studies comparing ALA-TAG with other forms (such as diacylglycerols) suggest that its metabolic effects may be less pronounced than those of diacylglycerol-based formulations[2]. The primary indication for use is as a dietary supplement or functional food ingredient aimed at supporting heart health or managing dyslipidemia.

Other names
ALA-enriched TAGALA-TAGalpha-linolenic acid-rich triacylglycerol
02

Targets

NF-κB

Beyond the preview

Go deeper on alpha-linolenic acid-enriched triacylglycerol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alpha-linolenic acid-enriched triacylglycerol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call